17,198.00 110.00(0.64%)
Open Price (₹)
Prev. Close (₹)
Volume (No’s)
Market Cap (₹)
Low Price (₹)
High Price (₹)
OI(₹)
Market Cap(₹Cr.)
P/E (TTM)
Book value (₹)
Div Yield (%)
EPS (TTM)
Face Value (₹)
Key Level
Resistance 1
Resistance 2
Support 1
Support 2
Moving Average
30 Days
50 Days
100 Days
200 Days
This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.
If I had made LUMPSUM investment of ₹ Returns(%)
in 12 36 60 Months Ago
My investment would be worth₹ with a Loss of
Incorporated on January 7, 1984, Neuland Laboratories Limited (NLL) is promoted by Davuluri Sucheth Rao. The Company is engaged in manufacturing and selling of bulk drugs such as Salbutamol Sulphate, Terbutaline Sulphate, Labetalol Hydrochloride and Ciprofloxacin. Neuland Drugs & Pharmaceuticals Pvt. Ltd., a company set up by the same promoters to manufacture bulk drugs was merged with the Company effective from April, 1992. NLL manufactures bulk drugs.The Company came out with its initial public offering in Apr.'94 at a premium of Rs 35 aggregating Rs 5.69 cr, to part-finance the capacity expansion to manufacture bulk drugs and to diversify its product-mix. The cost of the project as estimated by ICICI was Rs 15.7 cr.NLL's products are exported to more than 35 countries including Germany, Italy, Switzerland, the UK and the Netherlands. The company is also negotiating with multinational companies for tying up supplies of Ranitidine Hydrochloride Form I and Salbutamol Sulphate.During the year 1999-2000, the company introduced Itraconazole, an anti-fungal drug and Ipratropium Bromide, an anti-asthmatic drug and the R & D has developed a process for manufacture of Oflaxacin for Regulatory Markets. The Pashamylaram unit has received USFDA approval for manufacturing of R...